| Vol. 5.11 – 26 March, 2021 |
| |
|
|
| Tumor necrosis factor‐α‐induced protein 8‐like 2 suppressed nonalcoholic fatty liver disease (NAFLD) advancement by blocking transforming growth factor‐beta‐activated kinase 1‐c‐Jun NH2‐terminal kinase/p38 pathway and was a promising target molecule for NAFLD therapy. [Hepatology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that polyadenylate-binding protein 1 (circPABPC1) was preferentially lost in tumor cells from clinical samples and inhibited both intrahepatic and distant metastases in a mouse xenograft model. [Science Advances] |
|
|
|
| Researchers showed that checkpoint kinase 2 (CHK2), a central effector of DNA damage response, regulated cellular energy production by affecting glycolysis and mitochondrial functions. [Cancer Research] |
|
|
|
| Scientists demonstrated that gene related to anergy in lymphocytes regulated the lipid accumulation in hepatic steatosis via interaction with sirtuin 1. [Cell Death & Disease] |
|
|
|
| The authors explored the effect of supplementary S-adenosylmethionine, which was the main biological methyl donor in mammalian cells, in regulating AT1R-associated protein (ATRAP), which was the negative regulator of AT1R. [Cell Death & Disease] |
|
|
|
| IRF-1 induced miR-195 to suppress CHK1 protein expression. Both increased IRF-1 and decreased CHK1 upregulate cellular apoptosis and PD-L1 expression in HCC. [British Journal of Cancer] |
|
|
|
| Researchers revealed that c-Jun was bound to the TGF-β receptor II (TGFBR2) promoter, whereas N-n-Butyl haloperidol iodide suppressed the binding of c-Jun to the TGFBR2 promoter to restrain TGF-β signaling and inhibit α-smooth muscle actin and collagen I upregulation. [Acta Pharmacologica Sinica] |
|
|
|
| LINC01419 enhanced the methylation of zinc finger of the cerebellum (ZIC1) promoter, inhibited ZIC1 expression, and activated the PI3K/Akt signaling pathway, thereby enhancing the malignant phenotypes of hepatocellular carcinoma cells in vitro as well as tumor formation and metastasis in vivo. [Laboratory Investigation] |
|
|
|
| Scientists report the use of a nanofibrous hydrogel as a 3D scaffold for the culture and maintenance of functional primary human hepatocytes. [Scientific Reports] |
|
|
|
| Researchers revealed a metabolic inter-tissue cross-talk that linked skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. [Nature Metabolism] |
|
|
|
|
| The authors make the case that physiologically direct hepatic insulin action dominates acute suppression of glucose production, but that there is also a delayed, second order regulation of this process via extrahepatic effects. [Cell Metabolism] |
|
|
|
|
| Terns Pharmaceuticals, Inc. announced the initiation of dosing in a Phase I clinical trial evaluating TERN-501, a selective thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β when compared with other THR-β agonists in development. [Terns Pharmaceuticals, Inc. (Intrado GlobeNewswire LLC.)] |
|
|
|
|
| September 5 – 8, 2021 Exeter, England, United Kingdom |
|
|
|
|
|
| Spark Therapeutics – Philadelphia, Pennsylvania, United States |
|
|
|
| Cancer Research Center of Lyon – Lyon, France |
|
|
|
| CyberCoders – San Diego, California, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| The University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
|